【摘要】：目的：通過對(duì)毓金方治療痰濕蘊(yùn)肺型中晚期非小細(xì)胞肺癌的臨床療效的觀察,證明毓金方在治療痰濕蘊(yùn)肺型中晚期非小細(xì)胞肺癌有很好的療效。方法：收集2014年6月到2015年12月黑龍江中醫(yī)藥大學(xué)附屬一院門診及住院中晚期非小細(xì)胞肺癌的患者60例,隨機(jī)分為兩組,每組30人。其診斷均經(jīng)組織病理學(xué)或者細(xì)胞學(xué)檢查證實(shí)。最后完成療程及病例完整者只有59例,其中治療組30例和對(duì)照組29例。治療組：毓金方+康萊特注射液治療,毓金方連服,康萊特注射液,連續(xù)靜脈滴注治療14天,休息2周,28天為一周期；對(duì)照組：康萊特注射液,連續(xù)靜脈滴注治療14天,休息2周,28天為一周期；治療組對(duì)照組均連續(xù)治療三周期。觀察和比較兩組治療前后近期療效、腫瘤標(biāo)志物CEA, ECOG,中醫(yī)證候評(píng)分的變化。結(jié)果：1.以RECIST為標(biāo)準(zhǔn)的近期療效觀察治療組的疾病控制率是86.67%,對(duì)照組疾病控制率為65.52%,組間比較p0.05有統(tǒng)計(jì)學(xué)意義,表明治療組優(yōu)于對(duì)照組。2.兩組組內(nèi)比較腫瘤標(biāo)志物CEA表達(dá)治療前后有顯著性差異p0.05,有統(tǒng)計(jì)學(xué)意義；兩組組間比較治療后腫瘤標(biāo)志物CEA表達(dá)有顯著性差異p0.05,有統(tǒng)計(jì)學(xué)意義,表明治療組優(yōu)于對(duì)照組。3.兩組組內(nèi)比較ECOG評(píng)分治療前與治療后有顯著性差異p0.05,有統(tǒng)計(jì)學(xué)意義；兩組組間比較治療后ECOG評(píng)分有顯著性差異p0.05,有統(tǒng)計(jì)學(xué)意義,表明治療組優(yōu)于對(duì)照組。4.兩組組內(nèi)比較中醫(yī)癥候積分治療前與治療后有顯著性差異p0.05,有統(tǒng)計(jì)學(xué)意義；兩組組間比較療后中醫(yī)癥候積分有顯著性差異p0.05,有統(tǒng)計(jì)學(xué)意義,表明治療組優(yōu)于對(duì)照組。結(jié)論：1.毓金方能有效提高疾病控制率；2.毓金方能顯著降低腫瘤標(biāo)志物CEA的水平；3.毓金方能顯著改善體力狀態(tài),降低ECOG評(píng)分；4.毓金方能顯著改善臨床癥狀,降低中醫(yī)癥候積分。
[Abstract]:Objective: to observe the clinical effect of Yujin recipe in treating middle and late stage non small cell lung cancer of phlegm dampness accumulation lung type, and to prove that Yujin prescription has good curative effect on middle and late non small cell lung cancer of phlegm dampness accumulation lung type. Methods: from June 2014 to December 2015, 60 patients with advanced non-small cell lung cancer (NSCLC) were randomly divided into two groups, 30 in each group. The diagnosis was confirmed by histopathology or cytology. There were only 59 cases with complete course of treatment and complete treatment, including 30 cases in the treatment group and 29 cases in the control group. Treatment group: Yujin Fang Kanglaite injection, Yujin Fang Lianfu, Kanglaite injection, continuous intravenous drip treatment for 14 days, rest for 2 weeks, 28 days as a cycle; Control group: Kanglaite injection, continuous intravenous drip treatment for 14 days, rest for 2 weeks, 28 days as a cycle, the treatment group were treated for three consecutive cycles. To observe and compare the short-term curative effect and the change of CEA, ECOG, syndrome score before and after treatment in the two groups. Results: 1. The disease control rate of the treatment group and the control group were 86.67 and 65.52, respectively. The comparison between the two groups had statistical significance, indicating that the treatment group was better than the control group. There was a significant difference between the two groups in the expression of tumor marker CEA before and after treatment (p0.05). There was a significant difference in the expression of tumor marker CEA between the two groups (p 0.05), which indicated that the treatment group was better than the control group (P < 0.05). There was a significant difference in ECOG score between the two groups before and after treatment (p0.05), and between the two groups after treatment, there was a significant difference in ECOG score (p0.05), which indicated that the treatment group was better than the control group (4. 05%). There was a significant difference between the two groups before and after treatment, with statistical significance. There was significant difference in TCM symptom score between the two groups (p0.05), which indicated that the treatment group was superior to the control group. Conclusion 1. Yujin prescription can effectively improve the disease control rate; 2. Yujin prescription could significantly reduce the level of tumor marker CEA. Yujin prescription can significantly improve the physical condition, reduce the ECOG score; 4. Yujin prescription can significantly improve clinical symptoms and reduce TCM symptom score.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R734.2

【參考文獻(xiàn)】

中國(guó)期刊全文數(shù)據(jù)庫 前10條

1 于濤;張秋生;齊擁軍;;康萊特對(duì)晚期肺癌患者癥狀及生活質(zhì)量的改善作用[J];中國(guó)藥業(yè);2015年23期

2 馬玲;尹蕾;王兵;趙欣;付雪艷;;茯苓研究進(jìn)展[J];亞太傳統(tǒng)醫(yī)藥;2015年12期

3 劉建民;涂強(qiáng);;青老年肺癌患者臨床特點(diǎn)對(duì)比研究[J];實(shí)用癌癥雜志;2015年06期

4 劉俊莉;李瑞霞;郭治;張敏;靳毅;宋新霞;;欖香烯聯(lián)合NP方案綜合治療晚期非小細(xì)胞肺癌的臨床觀察[J];實(shí)用癌癥雜志;2015年02期

5 張玄薇;王孝勛;梁臣艷;潘玉麗;龐紫連;;對(duì)葉百部化學(xué)成分及藥理作用研究進(jìn)展[J];亞太傳統(tǒng)醫(yī)藥;2015年03期

6 潘博;潘敏求;黎月恒;李東芳;李琳霈;;養(yǎng)陰清解法則辨證治療中晚期原發(fā)性非小細(xì)胞肺癌的臨床和實(shí)驗(yàn)研究[J];中國(guó)醫(yī)藥指南;2014年28期

7 孟曉;韓燕;徐詠梅;張青;富琦;趙文碩;王笑民;楊國(guó)旺;;180例晚期非小細(xì)胞肺癌患者中醫(yī)證候分布與組合規(guī)律[J];中華中醫(yī)藥雜志;2014年09期

8 仝自強(qiáng);;肺癌放射治療的研究進(jìn)展[J];中國(guó)衛(wèi)生產(chǎn)業(yè);2014年24期

9 高磊;徐濤;孫素芹;;參芪抗瘤方治療中晚期非小細(xì)胞肺癌的臨床探討[J];中外醫(yī)療;2014年23期

10 姚曉軍;劉倫旭;;肺癌的流行病學(xué)及治療現(xiàn)狀[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年08期

中國(guó)博士學(xué)位論文全文數(shù)據(jù)庫 前1條

1 劉雨桃;吉非替尼治療晚期非小細(xì)胞肺癌的療效與生存分析[D];北京協(xié)和醫(yī)學(xué)院;2012年

中國(guó)碩士學(xué)位論文全文數(shù)據(jù)庫 前5條

1 蔡陳浩;扶正抗癌方對(duì)TKIs治療EGFR非突變晚期NSCLC的增敏作用研究[D];廣州中醫(yī)藥大學(xué);2015年

2 朱美昌;沙參麥冬湯加減聯(lián)合化療治療晚期非小細(xì)胞肺癌的臨床觀察[D];湖北中醫(yī)藥大學(xué);2013年

3 劉為易;黃金昶教授中醫(yī)治療非小細(xì)胞肺癌經(jīng)驗(yàn)總結(jié)[D];北京中醫(yī)藥大學(xué);2013年

4 楊昌衛(wèi);扶正抗癌方聯(lián)合吉非替尼治療晚期非小細(xì)胞肺癌的臨床研究[D];廣州中醫(yī)藥大學(xué);2011年

5 高海利;健脾益腎法治療中晚期非小細(xì)胞肺癌的臨床觀察[D];廣州中醫(yī)藥大學(xué);2008年

，

本文編號(hào)：2344039